🇺🇸 FDA
Patent

US 7795267

Bicyclic piperazine compound having TGR23 antagonistic activity

granted A61PA61P1/14A61P25/28

Quick answer

US patent 7795267 (Bicyclic piperazine compound having TGR23 antagonistic activity) held by Takeda Pharmaceutical Company Limited expires Mon Sep 09 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Sep 14 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 09 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P1/14, A61P25/28, A61P3/06, A61P3/10